Pharma Exclusives Pressreleases
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Wednesday, July 23, 2025Lantern Pharma Inc a clinicalstage oncology company leveraging its proprietary RADR artificial intelligence AI platform to systematically transform drug discovery paradigms today announces that a heavily pretreated patient with aggressive Grade nong...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Wednesday, July 23, 2025Revolution Medicines Inca latestage clinical oncology company developing targeted therapies for patients with RASaddicted cancers today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
Tuesday, July 22, 2025AstraZeneca today announces billion of investment in the United States by building on Americas global leadership in medicines manufacturing and RD This investment is expected
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Tuesday, July 22, 2025Longeveron Inca clinical stage regenerative medicine biotechnology company developing cellular therapies for lifethreatening rare pediatric and chronic agingrelated conditions today announced that it has licensed an issued US patent
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
Tuesday, July 22, 2025Biogen Inctoday announced upcoming scientific presentations at the Alzheimers Association International Conference AAIC taking place July in Toronto Canada Data on LEQEMBI lecanemab will include month results from the Clarity AD openlabel extension...
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
Monday, July 21, 2025Positive highlevel results from the final overall survival OS analysis of the FLAURA Phase III trial showed AstraZenecas Tagrisso osimertinib with the addition of pemetrexed and platinumbased chemotherapy demonstrated
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Friday, July 18, 2025Lexicon Pharmaceuticals Inc today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain DPNP despite treatment with standard of care will be presented
Thermo Fisher Scientific, South African Medical Research Council and Department of Science Innovation and Technology Announce New Training Facility to Develop Next Generation
Thursday, July 17, 2025Thermo Fisher Scientific Inc the world leader in serving science and the South African Medical Research Council SAMRC an entity of the Department of Health together with South Africas Department of Science Innovation
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
Thursday, July 17, 2025The Bristol Myers SquibbPfizer Alliance today announced a new directtopatient option for purchasing Eliquis apixaban via our Alliances patient resource Eliquis Support The offering provides an opportunity for uninsured underinsured
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
Wednesday, July 16, 2025Lantern Pharma Inc a pioneering artificial intelligence AI company transforming oncology drug discovery and development today announced the launch of an innovative AIpowered module within its proprietary RADR platform
